VAXX Vaxxinity Inc - Ordinary Shares - Class A
1,341
$0.081
$0.0255
(45.95%)
| Watchers | 1,341 |
| 52-Wk Low | $0.0453 |
| 52-Wk High | $3.10 |
| Market Cap | $11.39M |
| Volume | 1.24M |
| 52-Wk High | $3.10 |
| 52-Wk Low | $0.0453 |
Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day SessionBenzinga • 27 days ago
read more...
Share to Feed
Presentation will address the Company's clinical data in Parkinson's diseaseCAPE CANAVERAL, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the...
CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported...
Vaxxinity, Inc. (NASDAQ:VAXX Get Free Report) shares dropped 4.5% during trading on Monday . The company traded as low as $0.71 and last traded at $0.72. Approximately 195,541 shares changed...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson's patientsLISBON, Portugal, March 07, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc...
Key Insights The considerable ownership by private companies in Vaxxinity indicates that they collectively have a...
Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys. A Phase 1 trial of...
CAPE CANAVERAL, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present...
CAPE CANAVERAL, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a research...